Methods for treating resistant diseases using triazole containing macrolides

a triazole and macrolide technology, applied in the field of resistant diseases, can solve the problems of limited clinical utility of this drug, inactiveness, and increased risk of pneumonia causing community-acquired respiratory infection, and achieve low resistance development potential, high activity in vitro and in vivo, and low potential

Inactive Publication Date: 2011-08-18
TETARD INC
View PDF49 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]Accordingly, a continuing need for new antibiotics and anti-bacterial agents remains. Further, those new agents would desirably have the property of a low potential for resistance development or induction, and a low potential for naturally occurring resistance.

Problems solved by technology

Further, TEL is not active against erm(B) group A streptococci (which are naturally TEL resistant).
Moreover, observed TEL toxicities have limited the clinical utility of this drug.
Thus, the problem of drug-resistant pneumococci causing community-acquired respiratory infection, especially in children, is likely to worsen with the spread of this clone.
Further, those new agents would desirably have the property of a low potential for resistance development or induction, and a low potential for naturally occurring resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating resistant diseases using triazole containing macrolides
  • Methods for treating resistant diseases using triazole containing macrolides
  • Methods for treating resistant diseases using triazole containing macrolides

Examples

Experimental program
Comparison scheme
Effect test

example

[0202]Staphylococci, β-Haemolytic and Viridans Group Streptococci. A collection of 2006-2007 clinical isolates were S tested by CLSI methods (M7-A7) with associated interpretive criteria (M100-S18) and supplements (2-5% LHB) for streptococcal tests. CEM-101, TEL (TEL) and 10 comparators were used versus 201 S. aureus (75 WT-MRSA, 75 WT-MSSA, 30 CA-MRSA, 17 VISA or hVISA, 7 VRSA), 100 coagulase-negative staphylococci (CoNS; 10 species), 100 β-haemolytic (BHS; 30 group A, 31 group B, 14 group C, 9 group F, 16 group G) and 51 viridans group streptococci (VGS; 5 species), see Table.

[0203]MSSA strains were slightly more CEM-101-S (MIC50, 0.06 μg / ml) that MRSA or CA-MRSA strains (MIC50, 0.12 μg / ml). VISA, hVISA and VRSA were generally more refractory to CEM-101 and TEL. CEM-101 was 2-fold more potent than TEL against all staphylococci. Streptococci were very S to CEM-101 (MIC90, 0.03-0.06 μg / ml) and TEL was 4-fold less active with non-S isolates of BHS observed. ERY-R staphylococci remain...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
pKaaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to view more

Abstract

Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 USC §119(e) to U.S. Provisional Application Ser. No. 61 / 108,110, filed on Oct. 24, 2008, U.S. Provisional Application Ser. No. 61 / 108,112, filed on Oct. 24, 2008, U.S. Provisional Application Ser. No. 61 / 108,134, filed on Oct. 24, 2008, U.S. Provisional Application Ser. No. 61 / 108,137, filed on Oct. 24, 2008, U.S. Provisional Application Ser. No. 61 / 108,168, filed on Oct. 24, 2008, and U.S. Provisional Application Ser. No. 61 / 162,109, filed on Mar. 20, 2009, the entire disclosure of each of which are incorporated herein by reference.TECHNICAL FIELD[0002]The invention described herein relates to the treatment of resistant diseases, or more particularly, diseases caused at least in part by one or more resistant organisms. In particular, the invention described herein relates to the treatment of resistant diseases, or more particularly, diseases caused at least in part by one or more resistant organi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7056A61P31/04
CPCA61K31/70A61K31/7056A61K31/706A61K31/7048A61K31/7052A61K31/424C07D498/04C07H17/08A61P1/00A61P1/04A61P11/00A61P29/00A61P31/00A61P31/04A61P33/02Y02A50/30
Inventor FERNANDES, PRABHAVATHI B.PEREIRA, DAVID E.
Owner TETARD INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap